RESUMO
AIMS: There is rising healthcare utilization related to the increasing incidence and prevalence of atrial fibrillation (AF) worldwide. Simplifying therapy and reducing hospital episodes would be a valuable development. The efficacy of a streamlined AF ablation approach was compared to drug therapy and a conventional catheter ablation technique for symptom control in paroxysmal AF. METHODS AND RESULTS: We recruited 321 patients with symptomatic paroxysmal AF to a prospective randomized, multi-centre, open label trial at 13 UK hospitals. Patients were randomized 1:1:1 to cryo-balloon ablation without electrical mapping with patients discharged same day [Ablation Versus Anti-arrhythmic Therapy for Reducing All Hospital Episodes from Recurrent (AVATAR) protocol]; optimization of drug therapy; or cryo-balloon ablation with confirmation of pulmonary vein isolation and overnight hospitalization. The primary endpoint was time to any hospital episode related to treatment for atrial arrhythmia. Secondary endpoints included complications of treatment and quality-of-life measures. The hazard ratio (HR) for a primary endpoint event occurring when comparing AVATAR protocol arm to drug therapy was 0.156 (95% CI, 0.097-0.250; P < 0.0001 by Cox regression). Twenty-three patients (21%) recorded an endpoint event in the AVATAR arm compared to 76 patients (74%) within the drug therapy arm. Comparing AVATAR and conventional ablation arms resulted in a non-significant HR of 1.173 (95% CI, 0.639-2.154; P = 0.61 by Cox regression) with 23 patients (21%) and 19 patients (18%), respectively, recording primary endpoint events (P = 0.61 by log-rank test). CONCLUSION: The AVATAR protocol was superior to drug therapy for avoiding hospital episodes related to AF treatment, but conventional cryoablation was not superior to the AVATAR protocol. This could have wide-ranging implications on how demand for AF symptom control is met. TRIAL REGISTRATION: Clinical Trials Registration: NCT02459574.
Assuntos
Fibrilação Atrial , Ablação por Cateter , Veias Pulmonares , Humanos , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/tratamento farmacológico , Fibrilação Atrial/cirurgia , Antiarrítmicos/efeitos adversos , Resultado do Tratamento , Estudos Prospectivos , Hospitais , Ablação por Cateter/efeitos adversos , Ablação por Cateter/métodos , Veias Pulmonares/cirurgia , RecidivaRESUMO
AIMS: Long-standing persistent atrial fibrillation (LSPAF) is challenging to treat with suboptimal catheter ablation (CA) outcomes. Thoracoscopic surgical ablation (SA) has shown promising efficacy in atrial fibrillation (AF). This multicentre randomized controlled trial tested whether SA was superior to CA as the first interventional strategy in de novo LSPAF. METHODS AND RESULTS: We randomized 120 LSPAF patients to SA or CA. All patients underwent predetermined lesion sets and implantable loop recorder insertion. Primary outcome was single procedure freedom from AF/atrial tachycardia (AT) ≥30 s without anti-arrhythmic drugs at 12 months. Secondary outcomes included clinical success (≥75% reduction in AF/AT burden); procedure-related serious adverse events; changes in patients' symptoms and quality-of-life scores; and cost-effectiveness. At 12 months, freedom from AF/AT was recorded in 26% (14/54) of patients in SA vs. 28% (17/60) in the CA group [OR 1.128, 95% CI (0.46-2.83), P = 0.83]. Reduction in AF/AT burden ≥75% was recorded in 67% (36/54) vs. 77% (46/60) [OR 1.13, 95% CI (0.67-4.08), P = 0.3] in SA and CA groups, respectively. Procedure-related serious adverse events within 30 days of intervention were reported in 15% (8/55) of patients in SA vs. 10% (6/60) in CA, P = 0.46. One death was reported after SA. Improvements in AF symptoms were greater following CA. Over 12 months, SA was more expensive and provided fewer quality-adjusted life-years (QALYs) compared with CA (0.78 vs. 0.85, P = 0.02). CONCLUSION: Single procedure thoracoscopic SA is not superior to CA in treating LSPAF. Catheter ablation provided greater improvements in symptoms and accrued significantly more QALYs during follow-up than SA. CLINICAL TRIAL REGISTRATION: ISRCTN18250790 and ClinicalTrials.gov: NCT02755688.
Assuntos
Fibrilação Atrial , Ablação por Cateter , Taquicardia Supraventricular , Fibrilação Atrial/cirurgia , Análise Custo-Benefício , Humanos , Anos de Vida Ajustados por Qualidade de Vida , Recidiva , Resultado do TratamentoRESUMO
The presence of left atrial thrombus is a contraindication to cardioversion or catheter ablation in patients with atrial fibrillation, due to the increased risk of systemic thromboembolism. Management of this situation includes changes in the anticoagulation regimen and repeat imaging tests. Accurate diagnosis of left atrial appendage thrombus is therefore essential but can sometimes be challenging. Multiple imaging modalities may sometimes be required in the setting of anatomical variations of the left atrial appendage and surrounding structures. We present the case of a patient awaiting ablation for atypical atrial flutter, who underwent a transthoracic echocardiogram that showed an echodense, mobile structure within the vicinity of the left atrial appendage, suggesting a possible thrombus. A cardiac CT demonstrated the image to correlate with an epicardial fat pad within the transverse sinus.
RESUMO
Atrial Fibrillation (AF) ablation using the cryoballoon is effective at reducing symptomatic AF episodes. The prevalence of AF is increasing with the aging population and access to such treatment would be enhanced by reducing the resource requirements. Relinquishing electrical mapping of the pulmonary veins (PV) removes the need for PV catheters, electrical recording equipment and staff trained in using this equipment. Moreover, the majority of complications are peri-procedural so overnight hospitalization maybe unnecessary. We tested this streamlined approach to AF ablation against medical therapy using the endpoint of time to all hospital episodes. METHODS: The AVATAR-AF study is a prospective, multicenter, randomized controlled trial testing the primary hypothesis that AF ablation done without PV mapping or overnight hospitalization is more effective than anti-arrhythmic drugs at reducing all hospital episodes related to recurrent atrial arrhythmias. We included a third arm to test a secondary hypothesis that confirming PV entrance block as per consensus guidelines can improve outcomes. Three hundred twenty-one patients with documented paroxysmal AF will be randomized in a 1:1:1 manner to one of three investigation arms: (1) AVATAR protocol cryoballoon ablation without assessment of acute PV isolation or overnight hospitalization; (2) medical therapy with anti-arrhythmic drugs; or (3) conventional cryoballoon ablation with assessment of acute PV isolation. The primary endpoint is defined as the time to all hospital episodes (including outpatient consultation) related to treatment for atrial arrhythmia. CONCLUSION: The AVATAR-AF study will determine whether the resource utilization for AF ablation can be reduced whilst maintaining superiority over medical therapy.
Assuntos
Antiarrítmicos/uso terapêutico , Fibrilação Atrial , Ablação por Cateter/métodos , Criocirurgia/métodos , Hospitalização , Veias Pulmonares/cirurgia , Ensaios Clínicos Controlados Aleatórios como Assunto , Procedimentos Cirúrgicos Ambulatórios/métodos , Fibrilação Atrial/tratamento farmacológico , Fibrilação Atrial/cirurgia , Estudos Cross-Over , Fenômenos Eletrofisiológicos , Humanos , Estudos Multicêntricos como Assunto , Estudos Prospectivos , Veias Pulmonares/fisiopatologia , Recidiva , Avaliação de Sintomas , Resultado do TratamentoRESUMO
BACKGROUND: Epicardial ablation complications are more frequent in patients with preexisting pericardial adhesions. As opposed to the dry puncture technique, the coronary vein exit and carbon dioxide (CO2) insufflation (EpiCO2) technique allows diagnosing pericardial adhesions before subxiphoid puncture. OBJECTIVE: This study aimed to evaluate the efficacy of the EpiCO2 technique in diagnosing pericardial adhesions prior to subxiphoid puncture. METHODS: Following coronary vein exit, contrast was injected in the pericardial space, and adhesions classified using our novel Brighton Adhesion Classification (BAC) into BAC-0 (no adhesions), BAC-1 (dispersed adhesions), and BAC-2 (dense adhesions extending to the entire assessed area). CO2 insufflation allowed subclassification of BAC-1 adhesions into BAC-1a (not preventing epicardial access or restricting catheter movement) and BAC-1b (either preventing epicardial access or significantly limiting catheter movement). RESULTS: Intentional coronary vein exit (right atrial appendage exit in 1 case) was achieved in all 235 consecutive epicardial ablation procedures undertaken at our center. A diagnosis of BAC-0 was made in 219 cases (93.2%), BAC-1a in 9 cases (3.8%), BAC-1b in 2 cases (0.9%), and BAC-2 in 5 cases (2.1%). This led to not attempting subxiphoid puncture in 6 cases (2.6%) and abandoning epicardial mapping because of limited catheter movement in 1 case (0.4%). Access-related complications occurred in 7 cases (3%) only in the BAC-0 group. CONCLUSION: The EpiCO2 technique allows assessment of the presence of pericardial adhesions prior to attempting subxiphoid puncture for epicardial access, which may lead to a reduction in the procedural complications within this subset of patients.
RESUMO
BACKGROUND AND AIMS: Symptom control for atrial fibrillation can be achieved by catheter ablation or drug therapy. We assessed the cost effectiveness of a novel streamlined atrial fibrillation cryoballoon ablation protocol (AVATAR) compared with optimised antiarrhythmic drug (AAD) therapy and a conventional catheter ablation protocol, from a UK National Health Service (NHS) perspective. METHODS: Data from the AVATAR study were assessed to determine the cost effectiveness of the three protocols in a two-step process. In the first stage, statistical analysis of clinical efficacy outcomes was conducted considering either a three-way comparison (AVATAR vs. conventional ablation vs. optimised AAD therapies) or a two-way comparison (pooled ablation protocol data vs. optimised AAD therapies). In the second stage, models assessed the cost effectiveness of the protocols. Costs and some of the clinical inputs in the models were derived from within-trial cost analysis and published literature. The remaining inputs were derived from clinical experts. RESULTS: No significant differences between the ablation protocols were found for any of the clinical outcomes used in the model. Results of a within-trial cost analysis show that AVATAR is cost-saving (£1279 per patient) compared with the conventional ablation protocol. When compared with optimised AAD therapies, AVATAR (pooled conventional and AVATAR ablation protocols efficacy) was found to be more costly while offering improved clinical benefits. Over a lifetime time horizon, the incremental cost-effectiveness ratio of AVATAR was estimated as £21,046 per quality-adjusted life-year gained (95% credible interval £7086-£71,718). CONCLUSIONS: The AVATAR streamlined protocol is likely to be a cost-effective option versus both conventional ablation and optimised AAD therapy in the UK NHS healthcare setting.
RESUMO
BACKGROUND: Long-term clinical outcomes of catheter ablation (CA) compared to thoracoscopic surgical ablation (SA) to treat patients with long-standing persistent atrial fibrillation (LSPAF) are not known. OBJECTIVE: The purpose of this study was to compare the long-term (36-month) clinical efficacy, quality of life, and cost-effectiveness of SA and CA in LSPAF. METHODS: Participants were followed up for 3 years using implantable loop recorders and questionnaires to assess the change in quality of life. Intention-to-treat analyses were used to report the findings. RESULTS: Of the 115 patients with LSPAF treated, 104 (90.4%) completed 36-month follow-up [CA: n = 57 (95%); SA: n = 47 (85%)]. After a single procedure without antiarrhythmic drugs, 7 patients (12%) in the CA arm and 5 (11%) in the SA arm [hazard ratio 1.22; 95% confidence interval (CI) 0.81-1.83; P = .41] were free from atrial fibrillation/tachycardia (AF/AT) ≥30 seconds at 36 months. Thirty-three patients (58%) in the CA arm and 26 (55%) in the SA arm (hazard ratio 1.04; 95% CI 0.57-1.88; P = .91) had their AF/AT burden reduced by ≥75%. The overall impact on health-related quality of life was similar, with mean quality-adjusted life year estimates of 2.45 (95% CI 2.31-2.59) for CA and 2.32 (95% CI 2.13-2.52) for SA. Estimated costs were higher for SA (mean £24,682; 95% CI £21,746-£27,618) than for CA (mean £18,002; 95% CI £15,422-£20,581). CONCLUSION: In symptomatic LSPAF, CA and SA were equally effective at achieving arrhythmia outcomes (freedom from AF/AT ≥30 seconds and ≥75% burden reduction) after a single procedure without antiarrhythmic drugs. However, SA is significantly more costly than CA.
Assuntos
Fibrilação Atrial , Ablação por Cateter , Análise Custo-Benefício , Qualidade de Vida , Toracoscopia , Humanos , Fibrilação Atrial/cirurgia , Fibrilação Atrial/fisiopatologia , Fibrilação Atrial/economia , Masculino , Feminino , Ablação por Cateter/métodos , Ablação por Cateter/economia , Pessoa de Meia-Idade , Resultado do Tratamento , Toracoscopia/métodos , Toracoscopia/economia , Seguimentos , Eletrocardiografia Ambulatorial/métodos , Eletrocardiografia Ambulatorial/economia , Idoso , Fatores de TempoRESUMO
AIMS: Despite the increasing number of device implants worldwide, little is known about the early and late complications of cardiac resynchronisation therapy (CRT) or the incidence of these complications in patients with different heart failure aetiologies. We aim to determine procedural success and early and late complications in CRT patients. METHODS AND RESULTS: All early (<90 days) and late (>90 days) complications occurring over 490 consecutive CRT procedures in 402 patients, from a large single-centre registry between 2000 and 2009 were analysed. Mean follow-up duration was 1012 ± 610 days. In addition, procedural data and long-term left ventricular (LV) lead performance were examined. The mean age of patients was 65 ± 15 years, 31% were female. The majority of devices (70%) were CRT-defibrillators. Left ventricular lead implantation was achieved after one or more than one attempt in 96.7% of patients (first procedure was successful in 95.1%). The incidence of early and late complications was 9.4% and 6.1% respectively. Infection and lead displacement were the most common complications. Dilated cardiomyopathy (DCM) was associated with significantly more complications than ischaemic cardiomyopathy (P = 0.01) and these occurred later in the DCM population. Long-term LV lead performance was comparable with that of right atrial and ventricular leads. CONCLUSION: Transvenous implantation of the LV lead is safe and achievable for CRT with high procedural success rates. For the first time we describe the late complications from CRT in different heart failure populations. This group of patients must be kept under surveillance, not only for heart failure events but also for device-related issues. The reasons for higher complication rates in DCM patients require further evaluation.
Assuntos
Terapia de Ressincronização Cardíaca/mortalidade , Cardiomiopatias/epidemiologia , Eletrodos Implantados/estatística & dados numéricos , Migração de Corpo Estranho/epidemiologia , Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/prevenção & controle , Infecções Relacionadas à Prótese/epidemiologia , Idoso , Dispositivos de Terapia de Ressincronização Cardíaca/estatística & dados numéricos , Comorbidade , Feminino , Ventrículos do Coração/cirurgia , Humanos , Incidência , Estudos Longitudinais , Masculino , Medição de Risco , Análise de Sobrevida , Taxa de Sobrevida , Resultado do Tratamento , Reino Unido/epidemiologiaRESUMO
Pulmonary vein occlusion (PVO) is a known complication of radiofrequency ablation for atrial fibrillation. We present a case with delayed presentation leading to chronic total PVO. Computed Tomography (CT) imaging did not predict the presence of residual flow. Despite this, the occlusion was successfully stented using wire escalation techniques adapted from chronic total occlusion coronary angioplasty, with resolution of symptoms. This emphasises the importance of combining CT with invasive angiography for patient selection and interventional strategy. Innovative angioplasty techniques used to overcome PVO need to be balanced against additional risk of perforation when dealing with extra-cardiac structures.
Assuntos
Fibrilação Atrial , Ablação por Cateter , Veias Pulmonares , Pneumopatia Veno-Oclusiva , Humanos , Veias Pulmonares/diagnóstico por imagem , Veias Pulmonares/cirurgia , Fibrilação Atrial/diagnóstico por imagem , Fibrilação Atrial/cirurgia , Pneumopatia Veno-Oclusiva/diagnóstico por imagem , Pneumopatia Veno-Oclusiva/etiologia , Pneumopatia Veno-Oclusiva/terapia , Angioplastia/efeitos adversos , Angiografia/efeitos adversos , Ablação por Cateter/efeitos adversosRESUMO
AIMS: To establish clinical factors affecting success in persistent atrial fibrillation (AF) ablation. METHODS AND RESULTS: Wide area circumferential ablation with linear and electrogram-based left atrial (LA) ablation was performed in 191 consecutive patients for persistent AF. After mean follow-up of 13.0 ± 8.9 months, overall success was 64% requiring a mean of 1.5 procedures. Single procedure success rate was 32%. Left atrial size was a univariate predictor of recurrence after a single procedure (P =0.04). Only LA size [hazard ratio (HR) 1.05/mm with 95% confidential interval (CI) 1.02-1.08] was an independent predictor of recurrence after a single procedure. Only LA size was a univariate predictor of recurrence after multiple procedures (P < 0.01). Left atrial size (HR 1.07/mm with 95% CI 1.02-1.11) and hypertrophic cardiomyopathy (HCM; HR 2.42 with 95% CI 1.06-5.55) were independent predictors of recurrence after multiple procedures. Ablation strategy did not affect success after a single procedure. Left atrial size of <43 mm predicted long-term success with a sensitivity of 92%, specificity 52%, positive predictive value 49%, and negative predictive value 93%. With LA size >43 mm, HCM (HR 3.09 with 95% CI 1.70-7.5) and AF duration (HR 1.07/year with 95% CI 1.00-1.13) were independent predictors of recurrence. CONCLUSION: Left atrial size is the major independent determinant of AF recurrence after ablation for persistent AF. This has important implications for patient selection for persistent AF ablation and the evaluation of AF ablation clinical trial results.
Assuntos
Fibrilação Atrial/cirurgia , Ablação por Cateter , Átrios do Coração/diagnóstico por imagem , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Seleção de Pacientes , Valor Preditivo dos Testes , Recidiva , Estudos Retrospectivos , Sensibilidade e Especificidade , Resultado do Tratamento , UltrassonografiaRESUMO
AIMS: An increasing number of transseptal punctures (TSPs) are performed worldwide for atrial ablations. Transseptal punctures can be complex and can be associated with potentially life threatening complications. The purpose of the study was to evaluate the safety and efficacy of a novel transseptal guidewire (TSGW) designed to facilitate TSPs. METHODS AND RESULTS: Transseptal punctures were performed using a SafeSept TSGW passed through a standard TSP apparatus. Transseptal punctures were performed by standard technique with additional use of a TSGW allowing probing of the interatrial septum without needle exposure and penetration of the fossa into the left atrium (LA). Transseptal puncture using the TSGW was performed in 210 patients. Left atrial access was achieved successfully in 205 of 210 patients (97.6%) and in 96.3% of patients undergoing repeat TSP. Left atrial access was achieved with the first pass in 81.2% (mean 1.4 ± 0.9 passes, range 1-6) using the TSGW. No serious complications were attributable to the use of the TSGW, even in cases of failed TSP. CONCLUSIONS: The TSGW is associated with a high success rate for TSP and may be a useful alternative to transoesophageal or intracardiac echocardiogram-guided TSP.
Assuntos
Ligas , Fibrilação Atrial/cirurgia , Septo Interatrial , Cateterismo Cardíaco/métodos , Ablação por Cateter/métodos , Átrios do Coração , Punções/instrumentação , Adulto , Idoso , Idoso de 80 Anos ou mais , Cateterismo Cardíaco/efeitos adversos , Cateterismo Cardíaco/instrumentação , Falha de Equipamento , Feminino , Fluoroscopia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do TratamentoRESUMO
OBJECTIVES: This multicenter registry aimed to assess the reproducibility and safety of intentional coronary vein exit and carbon dioxide insufflation to facilitate subxiphoid epicardial access in the setting of ventricular tachycardia ablation. BACKGROUND: Epicardial ablation for ventricular tachycardia is not a widespread technique due to the significant potential complications associated with subxiphoid puncture. The first experience in 12 patients showed that intentional coronary vein exit and carbon dioxide insufflation was technically feasible. METHODS: A branch of the coronary sinus was cannulated by means of a diagnostic JR4 coronary catheter. Intentional perforation at the distal portion of that branch was performed with a high tip load 0.014-inch angioplasty wire. A microcatheter was advanced over the wire into the pericardial space. Carbon dioxide was then insufflated into the pericardial space, allowing direct visualization of the anterior pericardial space to facilitate subxiphoid puncture. RESULTS: Intentional coronary vein exit was attempted in 102 consecutive patients in 16 different centers and successfully completed in 101 patients. Significant pericardial adhesions were confirmed in 3 patients, preventing carbon dioxide insufflation and epicardial ablation. None of the punctures were complicated with inadvertent right ventricular puncture or damage to a coronary artery. Significant bleeding (>80 ml) due to coronary vein exit occurred in 5 patients, without hemodynamic compromise. None of the patients required surgery. CONCLUSIONS: Coronary vein exit and carbon dioxide insufflation can be safely and reproducibly achieved to facilitate subxiphoid pericardial access in the setting of ventricular tachycardia ablation.
Assuntos
Ablação por Cateter , Taquicardia Ventricular , Arritmias Cardíacas , Ablação por Cateter/efeitos adversos , Humanos , Sistema de Registros , Reprodutibilidade dos Testes , Taquicardia Ventricular/cirurgiaRESUMO
We report a case of an iatrogenic atrial septal defect following left atrial ablation for persistent atrial fibrillation in a patient with a Fontan circulation. Transseptal puncture was performed with two sheaths across a single puncture and left atrial ablation undertaken. Post procedure the patient became cyanosed with right to left shunting. Transcatheter closure immediately improved symptoms and oxygen saturation.
Assuntos
Fibrilação Atrial/cirurgia , Ablação por Cateter/efeitos adversos , Comunicação Interatrial/diagnóstico , Comunicação Interatrial/etiologia , Atresia Tricúspide/cirurgia , Adulto , Feminino , Átrios do Coração/cirurgia , Comunicação Interatrial/cirurgia , Humanos , Imageamento por Ressonância Magnética , Dispositivo para Oclusão SeptalRESUMO
AIMS: The exact role of transoesphageal echo (TOE) prior to atrial fibrillation (AF) ablation remains unclear. This study examines the incidence and predictors of left atrial (LA) thrombus in patients undergoing AF ablation. METHODS AND RESULTS: Patients were treated with warfarin for at least 4 weeks prior to ablation. This was substituted with therapeutic dalteparin 3 days before the procedure. All patients underwent TOE to exclude LA thrombus. Six clinical risk factors for thrombus were defined, known to be risk factors for stroke in AF: age>75, diabetes, hypertension, valve disease, prior stroke, or transient ischaemic attack and cardiomyopathy. A total of 635 procedures were performed. The incidence of thrombus was 12/635 (1.9%) despite therapeutic anti-coagulation. Patients with thrombus had larger LA diameter, mean 50.6+/-6.2 mm vs. 44.2+/-7.6 (P=0.006). In univariate analysis, persistent AF [odds ratio (OR)=10.4 with 95% CI 1.8-19.1], hypertension [OR=11.7 with 95% CI 2.5-54.1], age>75 (OR=4.5 with 95% CI 1.2-17.2), and cardiomyopathy (OR 5.9 with 95% CI 1.8-19.1) were significantly associated with thrombus. In multivariate analysis, hypertension (OR=14.2 with 95% CI 2.6-77.5), age>75 (OR=8.1, 95% CI 1.5-44.9), and cardiomyopathy (OR=10.5 with 95% CI 2.6-77.5) were independently associated with thrombus. There was no thrombus in patients without clinical risk factors. CONCLUSION: In patients presenting for AF ablation, LA thrombus is only seen in those with clinical risk factors. TOE is indicated in this group but may be unnecessary in patients without clinical risk factors.
Assuntos
Fibrilação Atrial/diagnóstico por imagem , Fibrilação Atrial/cirurgia , Ablação por Cateter/estatística & dados numéricos , Ecocardiografia Transesofagiana/estatística & dados numéricos , Trombose/diagnóstico por imagem , Trombose/epidemiologia , Fibrilação Atrial/epidemiologia , Comorbidade , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Cuidados Pré-Operatórios/métodos , Cuidados Pré-Operatórios/estatística & dados numéricos , Prognóstico , Reprodutibilidade dos Testes , Medição de Risco/métodos , Fatores de Risco , Sensibilidade e Especificidade , Trombose/prevenção & controle , Resultado do Tratamento , Reino Unido/epidemiologiaRESUMO
With the expansion in catheter-based treatments for atrial fibrillation the number of transseptal punctures being performed by cardiac electrophysiologists has increased significantly. Although in general transseptal puncture is successful, in a small percentage of cases it cannot be achieved due to complex intraatrial anatomy. We report the case of a difficult transseptal puncture (TSP), performed where the conventional approach using a Brockenbrough needle sheath was unable to perforate the septum. TSP was only achieved using a novel technique assisted by an angioplasty wire.
Assuntos
Angioplastia/métodos , Fibrilação Atrial/cirurgia , Septo Interatrial/cirurgia , Ablação por Cateter/métodos , Punções/métodos , Idoso , Angioplastia/instrumentação , Ablação por Cateter/instrumentação , Humanos , Masculino , Punções/instrumentação , Resultado do TratamentoRESUMO
PURPOSE: Increasing numbers of transseptal punctures (TSP) are performed for different cardiac interventions, especially for left atrial (LA) ablation of atrial fibrillation (AF). Significant TSP-related complications may occur even by experienced operators. Any strategies to mitigate these should be adopted. Previous reports have confirmed the safety and efficacy of the first generation nitinol guidewire for TSP. The objective was to assess the safety and efficacy of a new nitinol 'needle free' SafeSept guidewire (NFSG) for TSP. The distal J-shaped tip (0.014 in.) of the NFSG is unchanged in design; however, the shaft is thicker (0.0315 in.) and stiffer. METHODS: This is a multicentre study evaluating TSP without a transseptal needle, using the NFSG via a standard transseptal sheath-dilator, in patients with an indication for TSP. RESULTS: A total of 145 consecutive unselected patients were studied. The mean patient age was 59 ± 15. Thirty-one (21.4%) were female and 43 (29.7%) had a previous procedure requiring TSP. The mean transverse LA diameter was 4.0 ± 0.8 cm. AF or LA tachycardia comprised the major indication for TSP (n = 115). Transesophageal echocardiography for direct guidance of TSP was utilised in cases performed under general anesthesia (n = 66, 45.5%). LA access by TSP using the NFSG was achieved successfully in 100% of cases after 1.6 ± 2.3 passes. There were no TSP or other major procedural complications. CONCLUSIONS: Use of the NFSG appears to be a safe and effective method in performing TSP. The major improvement in the design of the NFSG is that TSP can be performed without a transseptal needle and exchange for a standard guidewire is not required upon establishing LA access.
Assuntos
Fibrilação Atrial , Ablação por Cateter , Fibrilação Atrial/diagnóstico por imagem , Fibrilação Atrial/cirurgia , Cateterismo Cardíaco , Feminino , Átrios do Coração/cirurgia , Humanos , Punções , Resultado do TratamentoRESUMO
We present a case of a 36-year-old woman with highly symptomatic persistent atrial fibrillation (AF) refractory to sotalol, flecainide, and external direct current (DC) cardioversion. The patient underwent biatrial mapping and ablation procedure for AF. Both atria were characterized by refractory properties which were much shorter than reported previously. Global fibrillatory activity was present with a median cycle length of 120 ms (range: 62-143). Extensive map-guided ablation sets had to be delivered to both left and right sides before effective DC cardioversion enabled sinus rhythm (SR) restoration. The patient remained in SR at 9 months of follow-up.
Assuntos
Fibrilação Atrial/diagnóstico , Fibrilação Atrial/cirurgia , Mapeamento Potencial de Superfície Corporal/métodos , Adulto , Feminino , Humanos , Seleção de Pacientes , PrognósticoRESUMO
OBJECTIVES: This study assessed the feasibility of intentional coronary venous perforation and exit with subsequent pericardial carbon dioxide (CO2) insufflation as a novel method for assisting subxiphoid pericardial puncture in the setting of epicardial mapping and ablation for ventricular tachycardia. The technique required that coronary venous perforation would not lead to significant bleeding. BACKGROUND: Widespread adoption of first-line endoepicardial ventricular tachycardia ablation has not been taken up because of the risk of lacerating coronary vessels and puncturing the right ventricle with direct subxiphoid puncture. METHODS: A lateral branch of the coronary sinus was subselected using a diagnostic JR4 coronary catheter inside a steerable sheath, via femoral access, and a distal branch then perforated intentionally using a high tip load 0.014-inch angioplasty wire. Either a microcatheter or over-the-wire balloon was then passed over this into the pericardial space, allowing up to 150 ml of pericardial CO2 insufflation, which allowed direct visualization of subxiphoid anterior pericardial access using a microneedle technique. RESULTS: Intentional coronary vein exit was achieved in all 12 patients. In 1 patient, this confirmed widespread pericardial adhesions and therefore only endocardial VT ablation was undertaken. The other patients underwent successful pericardial CO2 insufflation and subxiphoid access allowing epicardial ventricular mapping and ablation. The immediate pericardial aspirate was dry or contained serous fluid in all but 1 patient. CONCLUSIONS: We report the first human transcoronary vein exit procedure. Coronary vein exit and subsequent percutaneous subxiphoid anterior access using a microneedle puncture after CO2 pericardial insufflation can be achieved reliably and safely.
Assuntos
Ablação por Cateter/métodos , Vasos Coronários/cirurgia , Insuflação/métodos , Taquicardia Ventricular/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Dióxido de Carbono/administração & dosagem , Cardiomiopatias/complicações , Mapeamento Epicárdico/métodos , Feminino , Humanos , Insuflação/instrumentação , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/complicações , Pericárdio/cirurgia , Punções/instrumentação , Punções/métodos , Taquicardia Ventricular/complicações , Processo XifoideRESUMO
BACKGROUND: Patient satisfaction is an indicator of quality of care and a key factor for patients' healthcare choices. Although atrial fibrillation (AF) ablation is now common, there are no published data on patient satisfaction during this procedure. METHODS: Anonymous patient satisfaction questionnaires were distributed to consecutive AF ablation patients over 6 months at a single center. RESULTS: Of 101 questionnaires returned, 51 % related to a first procedure. Pre-operative clinic experiences were good. Prior to ablation, 53 % reported receiving information leaflets, while 55 % reported using the Internet to search for further information. Mean anxiety pre-procedurally on a ten-point scale was 3.1 ± 2.9 and 97 % of patients felt prepared. Afterwards, however, 31 % found the experience not as expected, mainly due to being in more pain or more awake. A large number of patients recalled the procedure in detail, despite use of conscious sedation. Overall cath lab experience was good or excellent for the majority (79 %). Patients felt less well than expected immediately post-procedure and perceived a higher complication rate immediately after ablation (24 %) and at home (32 %) than reported by physicians (4.5 %). Despite this, 89 % would recommend an AF ablation to a friend or relative, and 96 % would recommend our institution. CONCLUSION: Our findings suggest that most patients are satisfied with the AF ablation experience, but this is not solely dependent on procedural success. Dissatisfaction occurs due to unmet expectations, particularly excess pain, i.e. greater than expected, during and after ablation. An improved consent process may improve patient experience. Physicians should also address initiatives to reduce pain during AF ablation.
Assuntos
Fibrilação Atrial/epidemiologia , Fibrilação Atrial/cirurgia , Ablação por Cateter/estatística & dados numéricos , Consentimento Livre e Esclarecido/estatística & dados numéricos , Satisfação do Paciente/estatística & dados numéricos , Complicações Pós-Operatórias/epidemiologia , Qualidade de Vida , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Fatores de Risco , Inquéritos e Questionários , Resultado do Tratamento , Reino Unido/epidemiologiaRESUMO
OBJECTIVE: To investigate whether catheter ablation of atrial fibrillation (AF) reduces stroke rate or mortality. METHODS: An international multicentre registry was compiled from seven centres in the U.K. and Australia for consecutive patients undergoing catheter ablation of AF. Long-term outcomes were compared with (1) a cohort with AF treated medically in the Euro Heart Survey, and (2) a hypothetical cohort without AF, age and gender matched to the general population. Analysis of stroke and death was carried out after the first procedure (including peri-procedural events) regardless of success, on an intention-to-treat basis. RESULTS: 1273 patients, aged 58±11 years, 56% paroxysmal AF, CHADS(2) score 0.7±0.9, underwent 1.8±0.9 procedures. Major complications occurred in 5.4% of procedures, including stroke/TIA in 0.7%. Freedom from AF following the last procedure was 85% (76% off antiarrhythmic drugs) for paroxysmal AF, and 72% (60% off antiarrhythmic drugs) for persistent AF. During 3.1 (1.0-9.6) years from the first procedure, freedom from AF predicted stroke-free survival on multivariate analysis (HR=0.30, CI 0.16 to 0.55, p<0.001). Rates of stroke and death were significantly lower in this cohort (both 0.5% per patient-year) compared with those treated medically in the Euro Heart Survey (2.8% and 5.3%, respectively; p<0.0001). Rates of stroke and death were no different from those of the general population (0.4% and 1.0%, respectively). CONCLUSION: Restoration of sinus rhythm by catheter ablation of AF is associated with lower rates of stroke and death compared with patients treated medically.